Addex Therapeutics Ltd (ADXN)
15.65
-3.09
(-16.49%)
USD |
NASDAQ |
Apr 24, 15:07
Addex Therapeutics Cash from Investing (TTM): -0.0076M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.0076M |
| September 30, 2023 | -0.0064M |
| June 30, 2023 | -0.0024M |
| March 31, 2023 | 0.0005M |
| December 31, 2022 | 0.0031M |
| September 30, 2022 | -0.0236M |
| June 30, 2022 | -0.0272M |
| March 31, 2022 | -0.0297M |
| December 31, 2021 | -0.0332M |
| Date | Value |
|---|---|
| September 30, 2021 | -0.0575M |
| June 30, 2021 | -0.0583M |
| March 31, 2021 | -0.0581M |
| December 31, 2020 | -0.0634M |
| September 30, 2020 | -0.0297M |
| June 30, 2020 | -0.0322M |
| March 31, 2020 | -0.0335M |
| December 31, 2019 | -0.0435M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-0.0634M
Minimum
Dec 2020
0.0031M
Maximum
Dec 2022
-0.0296M
Average
-0.0297M
Median
Sep 2020
Cash from Investing (TTM) Benchmarks
| AC Immune SA | 73.11M |
| CRISPR Therapeutics AG | 374.65M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 49.71M |
| MoonLake Immunotherapeutics | -25.18M |